Haleon's Results were Sluggish in Respiratory Health
Dow Jones07-30
0938 GMT - Haleon's results were notably poor in respiratory health, says RBC's James Edwardes Jones in a note. Respiratory results were prompted by a double-digit revenue decline in APAC, notably China, he adds. However, this was somewhat offset by areas like pain relief and digestive health, he adds. Overall, North America came in slightly ahead, while other regions were a bit weaker, he adds. Shares are down 0.7% at 377.10 pence.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments